Table 5.
Study | Year | No. of patients | Age (yr) | Overall survival | Prostate cancer survival | PSA free survival | Biochemical recurrence free survival |
---|---|---|---|---|---|---|---|
Freedland et al.13 | 2004 | 88 | <50 | – | – | 73% (5-yr) | – |
Loeb et al.16 | 2008 | 55 | <40 | – | – | – | 94.8% |
Lin et al.17 | 2009 | 30,338 | <55 | 85% (10-yr) | 87% (10-yr) | – | – |
Becker et al.18 | 2014 | 175 | <50 | – | – | – | 63% (10-yr) |
Kinnear et al.15 | 2016 | 182 | <50 | – | 98% | – | – |
PSA, prostate-specific antigen.